365 related articles for article (PubMed ID: 26983850)
1. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism.
Flynn R; Paz K; Du J; Reichenbach DK; Taylor PA; Panoskaltsis-Mortari A; Vulic A; Luznik L; MacDonald KK; Hill GR; Nyuydzefe MS; Weiss JM; Chen W; Trzeciak A; Serody JS; Aguilar EG; Murphy WJ; Maillard I; Munn D; Koreth J; Cutler CS; Antin JH; Ritz J; Waksal SD; Zanin-Zhorov A; Blazar BR
Blood; 2016 Apr; 127(17):2144-54. PubMed ID: 26983850
[TBL] [Abstract][Full Text] [Related]
2. ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings.
Weiss JM; Chen W; Nyuydzefe MS; Trzeciak A; Flynn R; Tonra JR; Marusic S; Blazar BR; Waksal SD; Zanin-Zhorov A
Sci Signal; 2016 Jul; 9(437):ra73. PubMed ID: 27436361
[TBL] [Abstract][Full Text] [Related]
3. Targeting Bcl-6 prevents sclerodermatous chronic graft-versus-host disease by abrogating T follicular helper differentiation in mice.
Chen X; Wang Y; Huang X; Geng S; Li C; Zeng L; Huang L; Du X; Weng J; Lai P
Int Immunopharmacol; 2023 Apr; 117():109746. PubMed ID: 36827923
[TBL] [Abstract][Full Text] [Related]
4. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism.
Zanin-Zhorov A; Weiss JM; Nyuydzefe MS; Chen W; Scher JU; Mo R; Depoil D; Rao N; Liu B; Wei J; Lucas S; Koslow M; Roche M; Schueller O; Weiss S; Poyurovsky MV; Tonra J; Hippen KL; Dustin ML; Blazar BR; Liu CJ; Waksal SD
Proc Natl Acad Sci U S A; 2014 Nov; 111(47):16814-9. PubMed ID: 25385601
[TBL] [Abstract][Full Text] [Related]
5. Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease.
Paz K; Flynn R; Du J; Tannheimer S; Johnson AJ; Dong S; Stark AK; Okkenhaug K; Panoskaltsis-Mortari A; Sage PT; Sharpe AH; Luznik L; Ritz J; Soiffer RJ; Cutler CS; Koreth J; Antin JH; Miklos DB; MacDonald KP; Hill GR; Maillard I; Serody JS; Murphy WJ; Munn DH; Feser C; Zaiken M; Vanhaesebroeck B; Turka LA; Byrd JC; Blazar BR
Am J Transplant; 2019 Jun; 19(6):1820-1830. PubMed ID: 30748099
[TBL] [Abstract][Full Text] [Related]
6. ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis.
Nalkurthi C; Schroder WA; Melino M; Irvine KM; Nyuydzefe M; Chen W; Liu J; Teng MWL; Hill GR; Bertolino P; Blazar BR; Miller GC; Clouston AD; Zanin-Zhorov A; MacDonald KPA
JHEP Rep; 2022 Jan; 4(1):100386. PubMed ID: 34917911
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease.
Paz K; Flynn R; Du J; Qi J; Luznik L; Maillard I; MacDonald KP; Hill GR; Serody JS; Murphy WJ; Sage PT; Sharpe AH; Miklos D; Cutler CS; Koreth J; Antin JH; Soiffer RJ; Ritz J; Bradner JE; Melnick AM; Blazar BR
Blood; 2019 Jan; 133(1):94-99. PubMed ID: 30279226
[TBL] [Abstract][Full Text] [Related]
8. Blockade of p38 Mitogen-Activated Protein Kinase Inhibits Murine Sclerodermatous Chronic Graft-versus-Host Disease.
Matsushita T; Date M; Kano M; Mizumaki K; Tennichi M; Kobayashi T; Hamaguchi Y; Hasegawa M; Fujimoto M; Takehara K
Am J Pathol; 2017 Apr; 187(4):841-850. PubMed ID: 28189565
[TBL] [Abstract][Full Text] [Related]
9. The selective ROCK2 inhibitor KD025 reduces IL-17 secretion in human peripheral blood mononuclear cells independent of IL-1 and IL-6.
Tengesdal IW; Kitzenberg D; Li S; Nyuydzefe MS; Chen W; Weiss JM; Zhang J; Waksal SD; Zanin-Zhorov A; Dinarello CA
Eur J Immunol; 2018 Oct; 48(10):1679-1686. PubMed ID: 30098001
[TBL] [Abstract][Full Text] [Related]
10. Notch signaling mediated by Delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice.
Radojcic V; Paz K; Chung J; Du J; Perkey ET; Flynn R; Ivcevic S; Zaiken M; Friedman A; Yan M; Pletneva MA; Sarantopoulos S; Siebel CW; Blazar BR; Maillard I
Blood; 2018 Nov; 132(20):2188-2200. PubMed ID: 30181175
[TBL] [Abstract][Full Text] [Related]
11. Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease.
Belle L; Fransolet G; Somja J; Binsfeld M; Delvenne P; Drion P; Hannon M; Beguin Y; Ehx G; Baron F
PLoS One; 2016; 11(12):e0167997. PubMed ID: 27942010
[TBL] [Abstract][Full Text] [Related]
12. Extrafollicular CD4
Deng R; Hurtz C; Song Q; Yue C; Xiao G; Yu H; Wu X; Muschen M; Forman S; Martin PJ; Zeng D
Nat Commun; 2017 Oct; 8(1):978. PubMed ID: 29042531
[TBL] [Abstract][Full Text] [Related]
13. Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production.
Du J; Paz K; Flynn R; Vulic A; Robinson TM; Lineburg KE; Alexander KA; Meng J; Roy S; Panoskaltsis-Mortari A; Loschi M; Hill GR; Serody JS; Maillard I; Miklos D; Koreth J; Cutler CS; Antin JH; Ritz J; MacDonald KP; Schacker TW; Luznik L; Blazar BR
Blood; 2017 May; 129(18):2570-2580. PubMed ID: 28254742
[TBL] [Abstract][Full Text] [Related]
14. Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease.
Flynn R; Allen JL; Luznik L; MacDonald KP; Paz K; Alexander KA; Vulic A; Du J; Panoskaltsis-Mortari A; Taylor PA; Poe JC; Serody JS; Murphy WJ; Hill GR; Maillard I; Koreth J; Cutler CS; Soiffer RJ; Antin JH; Ritz J; Chao NJ; Clynes RA; Sarantopoulos S; Blazar BR
Blood; 2015 Jun; 125(26):4085-94. PubMed ID: 25852057
[TBL] [Abstract][Full Text] [Related]
15. Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice.
Daenthanasanmak A; Iamsawat S; Chakraborty P; Nguyen HD; Bastian D; Liu C; Mehrotra S; Yu XZ
Blood; 2019 Jan; 133(3):266-279. PubMed ID: 30514750
[TBL] [Abstract][Full Text] [Related]
16. ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease.
Jagasia M; Lazaryan A; Bachier CR; Salhotra A; Weisdorf DJ; Zoghi B; Essell J; Green L; Schueller O; Patel J; Zanin-Zhorov A; Weiss JM; Yang Z; Eiznhamer D; Aggarwal SK; Blazar BR; Lee SJ
J Clin Oncol; 2021 Jun; 39(17):1888-1898. PubMed ID: 33877856
[TBL] [Abstract][Full Text] [Related]
17. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease.
Le Huu D; Kimura H; Date M; Hamaguchi Y; Hasegawa M; Hau KT; Fujimoto M; Takehara K; Matsushita T
J Dermatol Sci; 2014 Jun; 74(3):214-21. PubMed ID: 24679982
[TBL] [Abstract][Full Text] [Related]
18. PIAS3 suppresses acute graft-versus-host disease by modulating effector T and B cell subsets through inhibition of STAT3 activation.
Lee SH; Moon SJ; Park MJ; Kim EK; Moon YM; Cho ML
Immunol Lett; 2014 Jul; 160(1):79-88. PubMed ID: 24718277
[TBL] [Abstract][Full Text] [Related]
19. Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1.
Leng C; Gries M; Ziegler J; Lokshin A; Mascagni P; Lentzsch S; Mapara MY
Exp Hematol; 2006 Jun; 34(6):776-87. PubMed ID: 16728283
[TBL] [Abstract][Full Text] [Related]
20. Combinatorial inhibition of Tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease.
Palaniyandi S; Strattan E; Kumari R; Mysinger M; Hakim N; Kesler MV; Apatira M; Bittencourt F; Wang L; Jia Z; Gururaja TL; Hill RJ; Hildebrandt GC
Bone Marrow Transplant; 2023 Aug; 58(8):924-935. PubMed ID: 37160943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
